iData Insights

Cognitive Impairment - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Dec 01, 2015 16:24 IST

Cognitive Impairment - Pipeline Review, H2 2015 Summary Global Markets Direct s, Cognitive Impairment - Pipeline Review, H2 2015, provides an overview of the Cognitive Impairments therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC @

To Get Sample Copy of Report visit @

Table of Contents

Table of Contents

2 List of Tables

7 List of Figures

9 Introduction

10 Global Markets Direct Report Coverage

10 Cognitive Impairment Overview

11 Therapeutics Development

12 Pipeline Products for Cognitive Impairment - Overview

12 Pipeline Products for Cognitive Impairment - Comparative Analysis

13 Cognitive Impairment - Therapeutics under Development by Companies

14 Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes

19 Cognitive Impairment - Pipeline Products Glance

21 Late Stage Products

21 Clinical Stage Products

22 Early Stage Products

23 Cognitive Impairment - Products under Development by Companies

24 Cognitive Impairment - Products under Investigation by Universities/Institutes

31 Cognitive Impairment - Companies Involved in Therapeutics Development

32 AbbVie Inc.

32 Actinogen Limited

33 Addex Therapeutics Ltd

34 Amarantus Bioscience Holdings, Inc.

35 Astellas Pharma Inc.

36 AstraZeneca Plc

37 Avineuro Pharmaceuticals, Inc.

38 Avraham Pharmaceuticals Ltd.

39 Boehringer Ingelheim GmbH

40 Bristol-Myers Squibb Company

41 Cardax Pharmaceuticals, Inc.

42 CereSpir Incorporated

43 Cognition Therapeutics, Inc.

44 D-Pharm Ltd. 45 Eisai Co., Ltd.

46 Eli Lilly and Company

47 Evotec AG

48 F. Hoffmann-La Roche Ltd.

49 FORUM Pharmaceuticals Inc.

50 H. Lundbeck A/S

51 Heptares Therapeutics Limited

52 Impel NeuroPharma, Inc.

53 Intra-Cellular Therapies, Inc.

54 Iproteos S.L.

55 Merck & Co., Inc.

56 Mnemosyne Pharmaceuticals, Inc.

57 Neuralstem, Inc.

58 Neuron Biopharma SA

59 Octapharma AG 60 Omeros Corporation

61 Pacific Northwest Biotechnology, LLC

62 Panacea Pharmaceuticals, Inc.

63 Pfizer Inc.

64 Pherin Pharmaceuticals, Inc.

65 Sage Therapeutics

66 Saniona AB

67 Shire Plc

68 Siena Biotech S.p.A.

69 SK Biopharmaceuticals Co., Ltd.

70 Sunovion Pharmaceuticals Inc.

71 Suven Life Sciences Ltd.

72 Takeda Pharmaceutical Company Limited

73 Teva Pharmaceutical Industries Limited 74 Upsher-Smith Laboratories, Inc.

75 Vanda Pharmaceuticals Inc.

76 Vicore Pharma AB

77 Virogenomics, Inc.

78 Cognitive Impairment - Therapeutics Assessment

79 Assessment by Monotherapy Products

79 Assessment by Target

80 Assessment by Mechanism of Action 88 Assessment by Route of Administration

95 Assessment by Molecule Type

98 Drug Profiles

101 A-431404 - Drug Profile

101 ADX-92639 - Drug Profile

102 AN-761 - Drug Profile

103 AP-61 - Drug Profile

104 AQW-051 - Drug Profile

105 ASP-4345 - Drug Profile

106 ASP-5736 - Drug Profile

107 AUT-1 - Drug Profile

108 AUT-6 - Drug Profile

109 AUT-9 - Drug Profile

110 AVL-3288 - Drug Profile

111 AVN-211 - Drug Profile

112 BAN-2401 - Drug Profile

113 BCA-909 - Drug Profile

115 BI-409306 - Drug Profile

117 BNC-375 - Drug Profile

119 C-21 - Drug Profile

120 CDX-085 - Drug Profile

122 CSP-1103 - Drug Profile

124 CT-0093 - Drug Profile

126 DAOI-B - Drug Profile

127 DP-NDD - Drug Profile

128 Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile

129 Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile

130 DSP-3748 - Drug Profile

131 E-1R - Drug Profile

132 eltoprazine - Drug Profile

133 encenicline hydrochloride - Drug Profile

135 erteberel - Drug Profile

138 EVT-501 - Drug Profile

139 HTL-9936 - Drug Profile

140 IB-AD - Drug Profile

141 IC-041 - Drug Profile

142 idursulfase - Drug Profile

143 immune globulin (human) - Drug Profile

145 insulin (human) - Drug Profile

148 IPR-001 - Drug Profile

149 IPR-088 - Drug Profile

150 IPR-19 - Drug Profile

151 irdabisant - Drug Profile

152 ITI-214 - Drug Profile

153 JAY-22233 - Drug Profile

154 ladostigil tartrate - Drug Profile

156 levetiracetam - Drug Profile

158 LS-1137 - Drug Profile

159 LUAF-64280 - Drug Profile

160 LY-3002813 - Drug Profile

161 NPS-0158 - Drug Profile

162 NS-9283 - Drug Profile

163 NSI-189 - Drug Profile

165 NSP-0163 - Drug Profile

167 NST-0037 - Drug Profile

168 NST-0076 - Drug Profile 169 NST-0078 - Drug Profile

170 O-1966 - Drug Profile 171 PAN-811 - Drug Profile

172 PF-04958242 - Drug Profile

174 PH-15 - Drug Profile

176 PNU-120596 - Drug Profile

177 RO-4938581 - Drug Profile

178 roflumilast - Drug Profile

179 RTL-551 - Drug Profile

182 SEN-15924 - Drug Profile

184 sepranolone - Drug Profile

185 SKL-15508 - Drug Profile

188 SKL-A4R - Drug Profile

189 Small Molecule 1 for Cognitive Impairment - Drug Profile

190 Small Molecule 10 for Cognitive Impairment - Drug Profile

191 Small Molecule 11 for Cognitive Impairment - Drug Profile

192 Small Molecule 12 for Cognitive Impairment - Drug Profile

193 Small Molecule 2 for Cognitive Impairment - Drug Profile

194 Small Molecule 3 for Cognitive Impairment - Drug Profile

195 Small Molecule 4 for Cognitive Impairment - Drug Profile

196 Small Molecule 5 for Cognitive Impairment - Drug Profile

197 Small Molecule 6 for Cognitive Impairment - Drug Profile

198 Small Molecule 7 for Cognitive Impairment - Drug Profile

199 Small Molecule 8 for Cognitive Impairment - Drug Profile

200 Small Molecule to Agonize Neuronal Acetylcholine Receptor Subunit Alpha-7 for Central Nervous System - Drug Profile

201 Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders - Drug Profile

202 Small Molecule to Antagonize Histamine 3 Receptor for Cognition - Drug Profile

203 Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile

204 Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment - Drug Profile

205 Small Molecule to Target GPR151 for CNS Diseases - Drug Profile

206 Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer - Drug Profile

207 Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile

208 Small Molecules to Agonize Alpha7 Acetylcholine Receptor for Cognitive Impairment - Drug Profile

209 Small Molecules to Agonize Beta-1 Adrenergic Receptor for Cognitive Impairment - Drug Profile

210 Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile 211 Small Molecules to Agonize GABA alpha 5 for Cognitive Impairment - Drug Profile

212 Small Molecules to Agonize GABAA Receptor for Cognitive Impairment - Drug Profile

213 Small Molecules to Agonize NMDA2B for CIAS - Drug Profile

214 Small Molecules to Antagonize 5-HT6 Receptors for Cognitive Impairment - Drug Profile

216 SUVN-501 - Drug Profile

218 SUVN-502 - Drug Profile

219 SUVN-507 - Drug Profile

221 SUVN-512 - Drug Profile

222 SUVN-976 - Drug Profile

223 TAK-058 - Drug Profile

224 TAK-915 - Drug Profile

225 tropisetron hydrochloride - Drug Profile

226 UE-2343 - Drug Profile 227 VU-0092273 - Drug Profile

228 xamoterol fumarate - Drug Profile

229 Cognitive Impairment - Recent Pipeline Updates

230 Cognitive Impairment - Dormant Projects

258 Cognitive Impairment - Discontinued Products

265 Cognitive Impairment - Product Development Milestones

266 Featured News & Press Releases

266 Appendix

276 Methodology 276 Coverage

276 Secondary Research

276 Primary Research

276 Expert Panel Validation

276 Contact Us

276 Disclaimer 277

Read More @

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

Contact Us:
iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.